{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:51:30Z","timestamp":1793055090093,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Suzhou 2023 annual science and technology development plan, Suzhou","award":["SKY2023152"],"award-info":[{"award-number":["SKY2023152"]}]},{"name":"Natural Science Research Project of Jiading Distric","award":["JDKW-2025-0024"],"award-info":[{"award-number":["JDKW-2025-0024"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01924-4","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T01:33:25Z","timestamp":1764034405000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Study on the regulation of Treg cell infiltration by EZH2 through CXCR4\/CXCL12 in diffuse large B-cell lymphoma"],"prefix":"10.1007","volume":"26","author":[{"given":"Hongxia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajun","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"7","key":"1924_CR1","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.3390\/cancers12071869","volume":"12","author":"AG Solimando","year":"2020","unstructured":"Solimando AG, Annese T, Tamma R, et al. New insights into diffuse large B-Cell lymphoma pathobiology. Cancers. 2020;12(7):1869.","journal-title":"Cancers"},{"issue":"1","key":"1924_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s13045-020-01011-z","volume":"13","author":"L Wang","year":"2020","unstructured":"Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13(1):175.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"1924_CR3","doi-asserted-by":"publisher","first-page":"805195","DOI":"10.3389\/fcell.2021.805195","volume":"7","author":"I Serganova","year":"2022","unstructured":"Serganova I, Chakraborty S, Yamshon S, et al. Epigenetic, metabolic, and immune crosstalk in germinal-center-derived B-cell lymphomas: unveiling new vulnerabilities for rational combination therapies. Front Cell Dev Biol. 2022;7(9):805195.","journal-title":"Front Cell Dev Biol"},{"issue":"9","key":"1924_CR4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.52586\/4970","volume":"26","author":"MK Liu","year":"2021","unstructured":"Liu MK, Sun XJ, Gao XD, et al. Methylation alterations and advance of treatment in lymphoma. Front Biosci (Landmark Ed). 2021;26(9):602\u201313.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"4","key":"1924_CR5","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1111\/cas.14840","volume":"112","author":"J Huang","year":"2021","unstructured":"Huang J, Gou H, Yao J, et al. The noncanonical role of EZH2 in cancer. Cancer Sci. 2021;112(4):1376\u201382.","journal-title":"Cancer Sci"},{"issue":"12","key":"1924_CR6","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3390\/jpm11121384","volume":"11","author":"S Petronilho","year":"2021","unstructured":"Petronilho S, Sequeira JP, Paulino S, et al. Prognostic value of histone modifying enzyme Ezh2 in Rchop-treated diffuse large B-cell lymphoma and high grade b-cell lymphoma. J Pers Med. 2021;11(12):1384.","journal-title":"J Pers Med"},{"issue":"9","key":"1924_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/modpathol.2016.114","volume":"29","author":"X Tian","year":"2016","unstructured":"Tian X, Pelton A, Shahsafaei A, et al. Differential expression of enhancer of zeste homolog 2 (EZH2) protein in small cell and aggressive B-cell non-Hodgkin lymphomas and differential regulation of EZH2 expression by p-ERK1\/2 and MYC in aggressive B-cell lymphomas. Mod Pathol. 2016;29(9):1050\u20137.","journal-title":"Mod Pathol"},{"issue":"8","key":"1924_CR8","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1182\/blood.2019000847","volume":"135","author":"J Kline","year":"2020","unstructured":"Kline J, Godfrey J, Ansell SM. The immune landscape and response to immune checkpoint blockade therapy in lymphoma. Blood. 2020;135(8):523\u201333.","journal-title":"Blood"},{"issue":"12","key":"1924_CR9","doi-asserted-by":"publisher","first-page":"741302","DOI":"10.3389\/fimmu.2021.741302","volume":"19","author":"J Huang","year":"2021","unstructured":"Huang J, Zhang J, Guo Z, et al. Easy or not-the advances of EZH2 in regulating T cell development, differentiation, and activation in antitumor immunity[J]. Front Immunol. 2021;19(12):741302.","journal-title":"Front Immunol"},{"issue":"51","key":"1924_CR10","doi-asserted-by":"publisher","first-page":"85624","DOI":"10.18632\/oncotarget.12928","volume":"7","author":"A Christofides","year":"2016","unstructured":"Christofides A, Karantanos T, Bardhan K, et al. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2[J]. Oncotarget. 2016;7(51):85624\u201340.","journal-title":"Oncotarget"},{"key":"1924_CR11","doi-asserted-by":"publisher","first-page":"108469","DOI":"10.1016\/j.intimp.2021.108469","volume":"104","author":"BJ Chen","year":"2022","unstructured":"Chen BJ, Zhao JW, Zhang DH, et al. Immunotherapy of cancer by targeting regulatory T cells. Int Immunopharmacol. 2022;104:108469.","journal-title":"Int Immunopharmacol"},{"issue":"13","key":"1924_CR12","doi-asserted-by":"publisher","first-page":"943354","DOI":"10.3389\/fimmu.2022.943354","volume":"1","author":"K Maharaj","year":"2022","unstructured":"Maharaj K, Uriepero A, Sahakian E, et al. Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies[J]. Front Immunol. 2022;1(13):943354.","journal-title":"Front Immunol"},{"issue":"5","key":"1924_CR13","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.3324\/haematol.2019.216218","volume":"105","author":"L Chen","year":"2020","unstructured":"Chen L, Ouyang J, Wienand K, et al. CXCR4 upregulation is an indicator of sensitivity to B-cell receptor\/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. Haematologica. 2020;105(5):1361\u20138.","journal-title":"Haematologica"},{"issue":"19","key":"1924_CR14","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.3390\/ijms20194740","volume":"20","author":"K Pansy","year":"2019","unstructured":"Pansy K, Feichtinger J, Ehall B, et al. The CXCR4-CXCL12-axis is of prognostic relevance in DLBCL and Its antagonists exert pro-apoptotic effects in vitro. Int J Mol Sci. 2019;20(19):4740.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1924_CR15","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3390\/cancers12071781","volume":"12","author":"YC Chien","year":"2020","unstructured":"Chien YC, Chen JN, Chen YH, Chou RH, Lee HC, Yu YL. Epigenetic silencing of miR-9 promotes migration and invasion by EZH2 in glioblastoma Cells. Cancers (Basel). 2020;12(7):1781.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"1924_CR16","doi-asserted-by":"publisher","first-page":"8494","DOI":"10.1038\/ncomms9494","volume":"25","author":"H Liu","year":"2015","unstructured":"Liu H, Liu Y, Liu W, et al. EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma. Nat Commun. 2015;25(6):8494.","journal-title":"Nat Commun"},{"issue":"3","key":"1924_CR17","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1111\/bjh.17366","volume":"193","author":"JM Rodrigues","year":"2021","unstructured":"Rodrigues JM, Nikkarinen A, Hollander P, et al. Infiltration of CD163-, PD-L1- and FoxP3-positive cells adversely affects outcome in patients with mantle cell lymphoma independent of established risk factors. Br J Haematol. 2021;193(3):520\u201331.","journal-title":"Br J Haematol"},{"issue":"1","key":"1924_CR18","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1038\/s41598-022-06877-2","volume":"12","author":"X Zhou","year":"2022","unstructured":"Zhou X, Guo S, Shi Y. Comprehensive analysis of the expression and significance of CXCLs in human diffuse large B-cell lymphoma. Sci Rep. 2022;12(1):2817.","journal-title":"Sci Rep"},{"issue":"3","key":"1924_CR19","first-page":"260","volume":"41","author":"Z Qingmin","year":"2021","unstructured":"Qingmin Z, Yongqi L, Jiawei L, et al. Co-culture methods of T cells and tumor cells and their application progress. Mod Immunol. 2021;41(3):260\u20134.","journal-title":"Mod Immunol"},{"issue":"2","key":"1924_CR20","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.bbrc.2017.12.072","volume":"495","author":"L Sadovska","year":"2018","unstructured":"Sadovska L, Zandberga E, Sagini K, et al. A novel 3D heterotypic spheroid model for studying extracellular vesicle-mediated tumour and immune cell communication. Biochem Biophys Res Commun. 2018;495(2):1930\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1924_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1080\/15384047.2017.1416932","volume":"19","author":"T Lianyuan","year":"2018","unstructured":"Lianyuan T, Dianrong X, Chunhui Y, et al. The predictive value and role of stromal tumor-infiltrating lymphocytes in pancreatic ductal adenocarcinoma (PDAC). Cancer Biol Ther. 2018;19(4):296\u2013305.","journal-title":"Cancer Biol Ther"},{"issue":"11","key":"1924_CR22","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.trecan.2023.07.015","volume":"9","author":"Q Zhao","year":"2023","unstructured":"Zhao Q, Liu Y, Li J, et al. Modulating treg stability to improve cancer immunotherapy. Trends Cancer. 2023;9(11):911\u201327.","journal-title":"Trends Cancer"},{"key":"1924_CR23","unstructured":"Zelenetz AD, Gordon LI, Abramson JS et al. NCCN Guidelines\u00ae Insights: B-Cell Lymphomas, Version 6.2023. J Natl Compr Canc Netw. 2023"},{"issue":"586","key":"1924_CR24","doi-asserted-by":"publisher","first-page":"216706","DOI":"10.1016\/j.canlet.2024.216706","volume":"1","author":"P Kaur","year":"2024","unstructured":"Kaur P, Shankar E, Gupta S. EZH2-mediated development of therapeutic resistance in cancer. Cancer Lett. 2024;1(586):216706.","journal-title":"Cancer Lett"},{"issue":"16","key":"1924_CR25","doi-asserted-by":"publisher","first-page":"5522","DOI":"10.1158\/0008-5472.CAN-10-3143","volume":"71","author":"E Righi","year":"2011","unstructured":"Righi E, Kashiwagi S, Yuan J, et al. CXCL12\/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011;71(16):5522\u201334.","journal-title":"Cancer Res"},{"issue":"52","key":"1924_CR26","doi-asserted-by":"publisher","first-page":"eaba0759","DOI":"10.1126\/sciimmunol.aba0759","volume":"5","author":"JC Lee","year":"2020","unstructured":"Lee JC, Mehdizadeh S, Smith J, et al. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol. 2020;5(52):eaba0759.","journal-title":"Sci Immunol."},{"issue":"11","key":"1924_CR27","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.7150\/ijbs.82317","volume":"19","author":"Y Yang","year":"2023","unstructured":"Yang Y, Li J, Lei W, et al. CXCL12-CXCR4\/CXCR7 Axis in cancer: from mechanisms to clinical applications. Int J Biol Sci. 2023;19(11):3341\u201359.","journal-title":"Int J Biol Sci"},{"issue":"177","key":"1924_CR28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.actbio.2024.02.007","volume":"15","author":"R Wei","year":"2024","unstructured":"Wei R, Li J, Lin W, et al. Nanoparticle-mediated blockade of CXCL12\/CXCR4 signaling enhances glioblastoma immunotherapy: monitoring early responses with MRI radiomics. Acta Biomater. 2024;15(177):414\u201330.","journal-title":"Acta Biomater"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01924-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01924-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01924-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:04:16Z","timestamp":1764079456000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01924-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1924"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01924-4","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"17 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Ethics Committee of Jiading District Central Hospital (No. RA-2023\u2013348). Pathological diagnosis was reviewed according to the 2017 WHO classification of hematopoietic and lymphoid tumors. These tumor specimens archived in the pathology department are retrospective cases and are considered discarded specimens with informed consent exemption.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The animal experiment protocol was carried out in accordance with the Guidelines for Animal Care and Use and was reviewed by the Laboratory Animal Welfare and Ethics Committee (IACUC Committee) of Saiye (Suzhou) Biotechnology Co., Ltd., and met the requirements of laboratory animal welfare and ethics (No. TACU23-FY028). All animal experiments were strictly implemented in compliance with the NIH Guide for the Care and Use of Laboratory Animals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal rights"}}],"article-number":"30"}}